Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets